ArticleThe Australasian journal of dermatology2025
Characteristics, Disease Burden and Healthcare Resource Use of Moderate and Severe Atopic Dermatitis in Australia.
Article in The Australasian journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Use of Dupilumab for Severe Atopic Dermatitis in Patients Aged Under 12-Years.The Australasian journal of dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND/
objectivesAtopic dermatitis (AD) affects up to 2.8 million Australians. This study examines the current characteristics of the disease and the burden placed on Australian adults living with moderate-to-severe AD.
methodA cross-sectional online survey of persons with moderate to severe AD (n = 300), enrolled in October 2024, was conducted, examining self-reported demographics, AD characteristics and burden of disease, including the Patient Oriented Eczema Measure (POEM) and the Dermatology Life Quality Index (DLQI). All analyses were descriptive and assessed by the following subgroups: moderate AD, severe AD and severe AD on advanced therapy.
resultThe mean (SD) age of participants was 38.2 (11.87) years, with 53.7% being female and 69.7% Caucasian. AD was active in 92.3% of participants, with a mean of 56.9 (65.9) active flare days in the past 6 months. The mean POEM score was 14.6 (5.90), and 90.7% reported disturbed sleep due to AD. Among employed respondents, the mean number of reduced workdays due to AD in the previous month was 3.2 (3.22). AD significantly impacted 59.0% of respondents' ability to engage in activities of interest. Co-morbidities were common, with 48.3% having at least one; the most prevalent being allergies (29.0%), anxiety (24.0%), and depression (13.7%).
conclusionNearly all participants experienced sleep disturbances, and the prevalence of anxiety and depression was high. Active flares in AD were frequent. Work and social impairment in moderate-to-severe AD was significant, including for many receiving currently available advanced therapies. There remains a need for new treatments in Australia to alleviate the current AD burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.